- Investing.com
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.
Metrics to compare | AZTR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAZTRPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.3x | −0.6x | −0.7x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 1.1x | 1.1x | 2.6x | |
Price / LTM Sales | - | 9.2x | 3.4x | |
Upside (Analyst Target) | - | 168.9% | 37.9% | |
Fair Value Upside | Unlock | 19.9% | 5.2% | Unlock |